Teleflex Incorporated Common Stock (TFX)
150.23
+0.36 (0.24%)
NYSE · Last Trade: Nov 5th, 3:14 PM EST
News & Press Releases
Teleflex Inc (TFX) Q3 2026 Earnings Call Transcriptfool.com
Divestiture proceeds are funding debt cuts and buybacks as Teleflex raises its outlook.
Via The Motley Fool · November 5, 2026
Teleflex (NYSE:TFX) posts Q3 2026 sales in line with estimates
Medical technology company Teleflex (NYSE:TFX) met Wall Street’s revenue expectations in Q3 2026, with revenue up 1.8% year on year to $567.8 million. Its no...
Via StockStory · November 5, 2026
Teleflex (NYSE:TFX) Earnings Beat Faces High Bar as Guidance Quality and Rally Draw Scrutinychartmill.com
Via Chartmill · November 5, 2026
Teleflex Announces Quarterly Dividend
Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 31, 2026, to shareholders of record at the close of business on November 16, 2026.
By Teleflex Incorporated · Via Business Wire · November 5, 2026
Teleflex Reports Third Quarter Financial Results and Full Year 2026 Outlook
Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 30, 2026.
By Teleflex Incorporated · Via Business Wire · November 5, 2026
Teleflex (TFX) to report earnings tomorrow: here is what to expect
Medical technology company Teleflex (NYSE:TFX) will be announcing earnings results this Thursday before the bell. Here’s what to look for. Teleflex beat anal...
Via StockStory · November 3, 2026
Teleflex Announces FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for its Freesolve™ Resorbable Magnesium Scaffold (RMS) for percutaneous coronary intervention (PCI).
By Teleflex Incorporated · Via Business Wire · October 22, 2026
Teleflex Announces Third Quarter 2026 Earnings Conference Call Information
Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 5, 2026.
By Teleflex Incorporated · Via Business Wire · October 22, 2026
1 Value Stock with Exciting Potential and 2 Facing Challenges
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...
Via StockStory · October 19, 2026
3 Healthcare Stocks We Find Risky
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...
Via StockStory · October 13, 2026
Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG™-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve™ Resorbable Magnesium Scaffold (RMS) in 35 mm and 40 mm lengths for the treatment of de novo coronary lesions up to 38 mm. The study reflects Teleflex's commitment to expanding clinical evidence supporting the use of the Freesolve™ RMS in percutaneous coronary intervention (PCI).
By Teleflex Incorporated · Via Business Wire · October 12, 2026
3 Small-Cap Stocks Walking a Fine Line
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Via StockStory · October 9, 2026
3 Healthcare Stocks That Concern Us
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...
Via StockStory · October 2, 2026
Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex
Check out the companies making headlines yesterday: PacBio (NASDAQ:PACB): Genomics company Pacific Biosciences of California (NASDAQ:PACB) rose by 5.8% on Mo...
Via StockStory · September 29, 2026
Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters during a 30-day period.1
By Teleflex Incorporated · Via Business Wire · September 29, 2026
Why Teleflex (TFX) Stock Is Trading Up Today
What Happened? Shares of medical technology company Teleflex (NYSE:TFX) jumped 4.5% in the afternoon session after BofA Securities upgraded the stock from Ne...
Via StockStory · September 28, 2026
3 Reasons to Avoid TFX and 1 Stock to Buy Instead
Even though Teleflex (currently trading at $122.08 per share) has gained 6.2% over the last six months, it has lagged the S&P 500’s 21.4% return during that ...
Via StockStory · September 28, 2026
Surgical Equipment & Consumables - Specialty Stocks Q2 Earnings Review: Teleflex (NYSE:TFX) Shines
Looking back on surgical equipment & consumables - specialty stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Teleflex (NY...
Via StockStory · September 8, 2026
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026.
By Teleflex Incorporated · Via Business Wire · September 8, 2026
Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technology is supported by the previously presented BIONETIC-TRA study, an investigator-initiated study with a 30-day follow-up period, that evaluated the safety and feasibility of the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System for the treatment of atherosclerotic iliac artery lesions using a trans-radial approach.
By Teleflex Incorporated · Via Business Wire · September 4, 2026
3 Unprofitable Stocks with Open Questions
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Via StockStory · August 20, 2026
Teleflex (TFX) Q2 2026 Earnings Call Transcriptfool.com
CEO Weidman discusses integration delays, FDA approvals, and capital allocation strategy.
Via The Motley Fool · August 13, 2026
Teleflex’s Q2 Earnings Call: Our Top 5 Analyst Questions
Teleflex’s second quarter was marked by revenue and non-GAAP earnings per share above Wall Street expectations, yet the operating margin declined significant...
Via StockStory · August 13, 2026
1 Small-Cap Stock with Competitive Advantages and 2 We Brush Off
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
Via StockStory · August 10, 2026
Teleflex Q2 Earnings Call Highlightsmarketbeat.com
Teleflex (NYSE:TFX) reported second-quarter revenue and adjusted earnings above its expectations, supported by strong growth in its Vascular and Surgical businesses, while slower-than-anticipated integration of its acquired Vascular Intervention business weighed on Interventional results.
Revenue f
Via MarketBeat · August 9, 2026